Patents Assigned to Viventia Biotechnologies Inc.
-
Publication number: 20130243799Abstract: The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immunoconjugates. The invention also relates to diagnostic and therapeutic methods and kits.Type: ApplicationFiled: January 25, 2013Publication date: September 19, 2013Applicant: VIVENTIA BIOTECHNOLOGIES INC.Inventors: Francina C. CHAHAL, Glen MACDONALD, Jeannick CIZEAU
-
Publication number: 20130217865Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.Type: ApplicationFiled: January 17, 2013Publication date: August 22, 2013Applicant: Viventia Biotechnologies Inc.Inventors: Nicholas Ronald Glover, Glen Christopher MacDonald, Joycelyn Entwistle, Jeannick Cizeau, Denis Bosc, Francina C. Chahal
-
Patent number: 8389286Abstract: The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immunoconjugates. The invention also relates to diagnostic and therapeutic methods and kits.Type: GrantFiled: April 26, 2011Date of Patent: March 5, 2013Assignee: Viventia Biotechnologies Inc.Inventors: Francina C. Chahal, Glen MacDonald, Jeannick Cizeau
-
Patent number: 8383117Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.Type: GrantFiled: June 10, 2005Date of Patent: February 26, 2013Assignee: Viventia Biotechnologies Inc.Inventors: Nicholas Ronald Glover, Glen Christopher MacDonald, Joycelyn Entwistle, Jeannick Cizeau, Denis Georges Bosc, Francina C. Chahal
-
Patent number: 8318472Abstract: An optimized nucleic acid sequence encoding the immunoconjugate VB4-845 is disclosed. Modifications to the original VB4-845 nucleic acid sequence include optimization of the sequences encoding the VH region, VL region, linkers and pseudomonas exotoxin A. The modifications improved the yield of VB4-845 in an Escherichia coli expression system.Type: GrantFiled: September 26, 2008Date of Patent: November 27, 2012Assignee: Viventia Biotechnologies Inc.Inventors: Jeannick Cizeau, Glen MacDonald, Arjune Premsukh
-
Patent number: 8273550Abstract: The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Heterogeneous Ribonucleoprotein G (HnRNPG). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies disclosed herein. Further, the application provides novel cancer-associated epitopes and antigens of variant HnRNPG, and uses thereof.Type: GrantFiled: October 23, 2008Date of Patent: September 25, 2012Assignee: Viventia Biotechnologies Inc.Inventors: Jeannick Cizeau, Francina C. Chahal
-
Patent number: 8263744Abstract: An optimized nucleic acid sequence encoding the immunoconjugate VB6-845 is described Modifications to the original VB6-845 include changes in the nucleic acid sequence encoding the VH region, CH region, CL region, VL region, the furm linker and the bouganm toxin. The optimized VB6-845 displays improved recombinant protein expression over the original in an E. coli expression system.Type: GrantFiled: April 18, 2008Date of Patent: September 11, 2012Assignee: Viventia Biotechnologies Inc.Inventors: Jeannick Cizeau, Glen Christopher Macdonald
-
Publication number: 20120128723Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.Type: ApplicationFiled: November 16, 2011Publication date: May 24, 2012Applicant: VIVENTIA BIOTECHNOLOGIES INC.Inventors: Francina C. CHAHAL, Joycelyn ENTWISTLE, Jeannick CIZEAU, Nicholas Ronald GLOVER, Glen Christopher MACDONALD
-
Publication number: 20120058106Abstract: The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immunoconjugates. The invention also relates to diagnostic and therapeutic methods and kits.Type: ApplicationFiled: April 26, 2011Publication date: March 8, 2012Applicant: VIVENTIA BIOTECHNOLOGIES INC.Inventors: FRANCINA C. CHAHAL, GLEN MACDONALD, JEANNICK CIZEAU
-
Patent number: 8084576Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.Type: GrantFiled: December 21, 2005Date of Patent: December 27, 2011Assignee: Viventia Biotechnologies Inc.Inventors: Nicholas Ronald Glover, Glen Christopher MacDonald, Joycelyn Entwistle, Jeannick Cizeau, Francina C. Chahal
-
Patent number: 7956162Abstract: The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immuno-conjugates. The invention also relates to diagnostic and therapeutic methods and kits.Type: GrantFiled: December 21, 2006Date of Patent: June 7, 2011Assignee: Viventia Biotechnologies Inc.Inventors: Francina C. Chahal, Glen MacDonald, Jeannick Cizeau